LabCorp San Diego 1311 2 Evening Creek Dr So Ste 200

San Dieao CA 9? 1?8- 4108 •o ' - - Phone·SSS- 668- 3700 Specimen Number I Patient iD Control N umber I Accmmt N tuuber I Accmmt Phone Number I Route

Patienr Last Name Accmmt Address Di rect Laboratory Services LLC

Patient First Name I Patient M iddle Name Interface Acct Patient SS# I Patient Phone Total Volume 4040 Florida Street Suite 202

Mandeville LA 70448 Age (YIM/D) I Date ofBit1h I Sex Fasting

Patient Address Additional h1fonn ation

Date and ~ime Collected I Date Entered I Date and Time Reponed Physician N ame I NPI I Physician ID

Tests Ordered CMP14+LP+TP+TSH+5AC+CBC/D/Plt; Hgb Ale with eAG Estimation; Testosterone, Free and Total; DHEA- Sulfate; Estradiol; Prostate- Specific Ag, Serum; C-Reactive Protein, Cardiac; Homocyst(e)ine, Plasma; Fibrinogen Activity; Venipuncture

I ACC: General Conunents

PID: I TESTS RESULT FLAG UNITS REFERENCE INTERVAL CMP1 4+LP+TP+TSH+5AC+CBC/ D/ P1 t Chemistries Glucose, Serum Uric Acid, Serum Please Note:

BUN Creatinine, Serum eGFR If NonAfricn Am eGFR If Africn Am BUN/ Creatini n e Rat i o Sodium, Serum Potass i um, Serum Chloride, Serum Carbon Dioxide, Total Calcium, Serum Phosphorus, Serum Protein, Total, Serum Albumin, Serum Globulin , Total A/G Rat i o Bi lirubin, Total Alkaline Phosphatase, s LDH AST (SGOT) ALT (SGPT) GGT Iron, Serum

Lipids Cholesterol, Total

11 /30/12 05:13 ET

90 7 . 6

mg / dL mg/dL

65 - 99 3.7 - 8 . 6

Therapeut i c target for gout patients: <6.0 23 mg/ dL 6 - 24

1.09 mg/ dL 0.76 - 1.27 75 mL / min / 1 .73 >59 87 mL / mi n / 1 . 73 >59 21 Hi gh 9 - 20

140 mmol / L 134 - 144 4 . 4 mmol / L 3.5 - 5.2 1 02 mmol / L 97 - 108

25 mmol / L 20 - 32 9.3 mg/ dL 8.7 - 10.2 3 . 3 mg / dL 2.5 - 4.5 7 . 4 g / dL 6.0 - 8 . 5 4 . 5 g / dL 3.5 - 5.5 2 . 9 g / dL 1.5 - 4.5 1 .6 1.1 - 2.5 0 . 5 mg / dL 0 . 0 - 1.2

68 I U/L 25 - 150 209 IU/ L 0 - 225

80 Hi gh I U/L 0 - 40 128 Hi gh I U/L 0 - 44

20 I U/L 0 - 65 95 ug / dL 4 0 - 155

183 mg/ dL 1 00 - 199

FINAL REPORT Page 1 of 3

LAB I

01 01 01 01

01 01

01 01 01 01 01 01 01 01

01 01 01 01 01 01 01 01 01 01

This document contains private and confidentia l health infonnation protected by state and federal law. If you have received this document in en or. please call 50 4 - 8 2 8-2 6 6 6

©2004-12 Laboratmy Corporation of America ® Holdings All Rights Reserved

DOC! Ver: 1.49

LabCorp San Diego 131 12 Evening Creek Dr So Ste 200

San Dieoo CA 9? I? 8-4108 "6" , - -Patient Name

Phone·SSS- 668- 3700 Specimen Nmnber

Account Number I Patient ID

I Control Number

I Date and Time Collected I Date Repo11ed Sex I Age(YIM/D)

I Date of Birth

TESTS RESULT FLAG UNITS REFERENCE INTERVAL Triglycerides 51 mg/ d L 0 - 149 HDL Cholesterol 60 mg / dL >39 Comment

According to ATP-III Guidelines , HDL-C >59 mg/ dL is considered a negative r i sk factor for CHD.

LDL Cholestero l Calc 113 High mg/ dL T . Chol/HDL Ratio 3.1 rat i o units

Thyroi d TSH 1 6. 510 High uiU/ mL Thy r oxine (T4 ) 4.1 Low ug/ dL T3 Uptake 25 % Free Thyroxine Index 1. 0 Low

CBC, Pl atelet Ct , and Di ff WBC 3 .3 Low x l OE3 / u L RBC 5.38 xlOE6 / uL Hemogl obi n 17 . 4 g / dL Hematocrit 50 . 9 % MCV 95 fL MCH 32.3 pg MCHC 34 . 2 g / dL RDW 12 . 4 % Plate l ets 1 67 x l OE3 / u L Neutrophils 55 % Lymphs 34 % Monocytes 1 0 % Eos 1 % Basos 0 % Neutrophi ls (Absol ute) 1 . 8 x l OE3 / u L Lymphs (Absolute) 1 . 1 x l OE3 / u L Monocytes(Absolute ) 0 . 3 x l OE3 / u L Eos (Absolute) 0 . 0 x l OE3 / u L Baso (Absolute ) 0 . 0 x l OE3 / u L Immature Granulocytes 0 % Immature Grans (Abs) 0 . 0 x l OE3 / uL

Hgb Ale with eAG Estima tion Hemoglobin Ale 5 . 3 %

Increased r i sk for d i abetes: 5 . 7 - 6 . 4 Di abetes: >6.4 Glycemi c control for adults wi th diabetes: <7 . 0

Estim . Avg Glu (eAG) 1 05 mg / d L

1 1 /30/ 1 2 05 : 13 ET FINAL REPORT

0 - 99 0 .0 - 5.0

0.450 - 4.5 00 4.5 - 12. 0

24 - 39 1.2 - 4.9

4.0 - 10 .5 4.14 - 5.8 0 12.6 - 17. 7 37.5 - 51. 0

79 - 97 26.6 - 33. 0 31.5 - 35.7 12.3 - 15.4

1 4 0 - 4 15 40 - 74 14 - 46

4 - 13 0 - 7 0 - 3

1 .8 - 7 . 8 0.7 - 4.5 0.1 - 1. 0 0 .0 - 0.4 0 .0 - 0 .2

0 - 2 0 .0 - 0 . 1

4. 8 - 5.6

Page 2 of 3

LAB I 01 01 01

01 01 01 01 01

01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01

01

This document contains private and confidential health infonnation protected by state and federal law. If you have received this document in enor, please call 5 0 4 - 82 8-2 6 6 6

©2004- 12 Laboratmy Corporation of America ® Holdings All Rights Reserved

DOC! Ver: 1.49

LabCorp LabCorp San Diego 131 12 Evening Creek Dr So Ste 200

S D. CA 92128 4108 858 668 3700 Pl labor.:~tory Corpor>~tion of Americ;~ an 1ego, ~ 10ne: - ~ ~

Patient Name Specimen Number

Account Number I Patient ID I Control Number I Date and Time Collected , I Date Repot1ed Sex I Age(YIM/D) I Date of Birth

TESTS RESULT FLAG UNITS REFERENCE INTERVAL Testosterone,Free and Total Testosterone, Serum 1292 High ng/dL 348 - 1197 Free Testosterone(Direct) 29.5 High pg/mL 7.2 - 24.0

DHEA-Sulfate 470.5 High ug/dL 51.7 - 295 . 0

Estradiol 57.1 High pg/mL 7.6 - 42.6 Roche ECLIA methodo logy

Prostate-Specific Ag, Serum Prostate Specific Ag, Serum 0.4 ng/mL 0 .0 - 4.0

Roche ECLIA methodology .

Accordi ng to the American Urological Associ at i on, Serum PSA should decrease and remain at undetectab le levels after radi cal prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/ mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absol ute evidence o f the presence or absence of mal i gnant d i sease .

C-Reactive Protein, Cardiac 0. 15 mg/L 0.00 - 3.00 Relative Risk for Future Cardiovascular Event

Low Average 1 . 00 High

Homocyst (e)ine, Plasma 1 0 . 4 umol / L 0 . 0

Fibrinogen Activity 260 mg/ dL 1 93

01 so LabCorp San Diego Dir: Kelli Ch ase, MD 13112 Evening Creek Dr So Ste 200, San Diego, CA 92 1 28 - 4108

02 BN LabCorp Burlington Dir: William F Hancock, MD 1447 York Court, Burlington, NC 27215-3361

For inquiries, the physician may contact Branc h: 800- 762-4344 Lab: 858- 668-3 700

<1 . 00 - 3.00

>3 . 00

- 15.0

- 423

11 /3 0/12 05 : 13 ET FINAL REPORT Page 3 of 3

LAB I

01 02

01

01

01

01

01

01

This document contains private and confidentia l health infonuation protected by state and federal law. If you have received this document in en or, please call 50 4 - B 2 B-2 6 6 6

©2004-12 Laboratmy Corporation of America ® Holdings All Rights Reserved

DOC! Ver: 1.49